Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

PHASE3CompletedINTERVENTIONAL
Enrollment

1,090

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Tuberculosis
Interventions
BIOLOGICAL

ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.

BIOLOGICAL

ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm

All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.

Trial Locations (2)

Unknown

Wuxi NO.5 People's Hospital, Wuxi

Shanghai Public Health clinical Center, Shanghai

All Listed Sponsors
collaborator

Shanghai Public Health Clinical Center

OTHER_GOV

collaborator

Tianjin Haihe Hospital

OTHER

collaborator

Air Force Military Medical University, China

OTHER

collaborator

Proswell Medical Corporation

INDUSTRY

collaborator

Wuhan Institute for Tuberculosis Control

OTHER

collaborator

Beijing Chest Hospital

OTHER

collaborator

Wuxi Hospital for Infectious Diseases

OTHER

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

collaborator

Fuzhou Pulmonary Hospital of Fujian

OTHER

collaborator

Zhenjiang Third People's Hospital

UNKNOWN

collaborator

Anhui Provincial Hospital

OTHER_GOV

collaborator

Shenzhen Third People's Hospital

OTHER

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT02623556 - Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen | Biotech Hunter | Biotech Hunter